Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor Fluctuations

Next Previous
Search
Trial Profile

An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor Fluctuations

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors IMPAX Laboratories

    • Most Recent Events

    • 18 Dec 2023 Results evaluating the safety and efficacy of IPX203, published in the Movement Disorders
    • 27 Apr 2023 Results of pooled analysis (n=630) assessing the safety of IPX203 in parkinson disease from multi-center, double-blind, randomized, active-controlled and an open-label extension Phase 3 trials, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 27 Apr 2023 Results assessing long-term safety and efficacy of IPX203, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top